Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

(2016) S. H. Swerdlow et al.   BLOOD

Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma

(2016) Mariano G. Cardenas et al.   JOURNAL OF CLINICAL INVESTIGATION

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

(2016) Stephan Stilgenbauer et al.   LANCET ONCOLOGY

Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements

(2015) Wei Wang et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas

(2015) B. Culjkovic-Kraljacic et al.   BLOOD

Abstract LB-062: XPO1 is a rational target for double and triple-hit aggressive B-cell lymphomas

(2015) Rossella Marullo et al.   CANCER RESEARCH

Differential Requirements for eIF4E Dose in Normal Development and Cancer

(2015) Morgan L. Truitt et al.   CELL

Identifying Drug-Target Selectivity of Small-Molecule CRM1/XPO1 Inhibitors by CRISPR/Cas9 Genome Editing

(2015) Jasper E. Neggers et al.   CHEMISTRY & BIOLOGY

Bcl-2 family of proteins as drug targets for cancer chemotherapy: the long way of BH3 mimetics from bench to bedside

(2015) Laura Vela et al.   CURRENT OPINION IN PHARMACOLOGY

Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma

(2015) Rebecca L. Goldstein et al.   JOURNAL OF CLINICAL INVESTIGATION

Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas

(2015) Clémentine Sarkozy et al.   LANCET ONCOLOGY

Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas

(2015) Munevver Cinar et al.   LEUKEMIA RESEARCH

MYC Alterations in Diffuse Large B-Cell Lymphomas

(2015) Kennosuke Karube et al.   SEMINARS IN HEMATOLOGY

MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy

(2015) Toril Holien et al.   Oncotarget

Epigenetic diversity in hematopoietic neoplasms

(2014) Rita Shaknovich et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis

(2014) A. M. Petrich et al.   BLOOD

CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer

(2014) Edmond Chipumuro et al.   CELL

A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E

(2014) S. Assouline et al.   HAEMATOLOGICA

Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis

(2014) Arianna Sabò et al.   NATURE

Targeting BCL2 for the Treatment of Lymphoid Malignancies

(2014) Mary Ann Anderson et al.   SEMINARS IN HEMATOLOGY

Selective targeting of the stress chaperome as a therapeutic strategy

(2014) Tony Taldone et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma

(2013) H. Horn et al.   BLOOD

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

(2013) S. Hu et al.   BLOOD

Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma

(2013) Bjoern Chapuy et al.   CANCER CELL

MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations

(2013) Mette Ø. Pedersen et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma

(2013) S. M. Aukema et al.   HAEMATOLOGICA

MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

(2013) A. Valera et al.   HAEMATOLOGICA

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy

(2013) Peter E. Czabotar et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma

(2013) T. Clozel et al.   Cancer Discovery

Aberration in DNA Methylation in B-Cell Lymphomas Has a Complex Origin and Increases with Disease Severity

(2013) Subhajyoti De et al.   PLoS Genetics

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

(2012) Tina Marie Green et al.   JOURNAL OF CLINICAL ONCOLOGY

Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

(2012) Nathalie A. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

The Oncogene eIF4E Reprograms the Nuclear Pore Complex to Promote mRNA Export and Oncogenic Transformation

(2012) Biljana Culjkovic-Kraljacic et al.   Cell Reports

Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target

(2011) R. Zappasodi et al.   BLOOD

BCL2 Predicts Survival in Germinal Center B-cell-like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab

(2011) J. Iqbal et al.   CLINICAL CANCER RESEARCH

Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression

(2011) Nana Sasaki et al.   EXPERIMENTAL HEMATOLOGY

A Unified Model of Mammalian BCL-2 Protein Family Interactions at the Mitochondria

(2011) Fabien Llambi et al.   MOLECULAR CELL

Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90

(2011) Kamalika Moulick et al.   Nature Chemical Biology

B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma

(2010) Matija Snuderl et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Double-hit B-cell lymphomas

(2010) S. M. Aukema et al.   BLOOD

A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo

(2010) Leandro C. Cerchietti et al.   CANCER CELL

Aberrant Epigenetic Landscape in Cancer: How Cellular Identity Goes Awry

(2010) María Berdasco et al.   DEVELOPMENTAL CELL

Rearrangement ofMYCIs Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab

(2010) Sharon Barrans et al.   JOURNAL OF CLINICAL ONCOLOGY

DNA methylation prevents CTCF-mediated silencing of the oncogeneBCL6in B cell lymphomas

(2010) Anne Y. Lai et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival

(2009) N. A. Johnson et al.   BLOOD

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

(2009) K. J. Savage et al.   BLOOD

Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin

(2009) S. Assouline et al.   BLOOD

Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations

(2009) N. Tomita et al.   HAEMATOLOGICA

Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations

(2009) N Niitsu et al.   LEUKEMIA

A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6–dependent B cell lymphomas

(2009) Leandro C Cerchietti et al.   NATURE MEDICINE

A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo

(2008) L. C. Cerchietti et al.   BLOOD

BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells

(2008) Stella M. Ranuncolo et al.   BLOOD CELLS MOLECULES AND DISEASES

Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc–Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice

(2008) Jianxia Guo et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY